Tobam Purchases 9,656 Shares of DexCom, Inc. $DXCM

Tobam increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 16.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,604 shares of the medical device company’s stock after buying an additional 9,656 shares during the period. Tobam’s holdings in DexCom were worth $4,620,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in DXCM. Gradient Investments LLC boosted its position in shares of DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after acquiring an additional 40,343 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after purchasing an additional 137,986 shares in the last quarter. Banco Santander S.A. increased its position in shares of DexCom by 28.9% in the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock worth $16,843,000 after purchasing an additional 56,062 shares during the last quarter. Banque Pictet & Cie SA increased its position in shares of DexCom by 58.2% in the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after purchasing an additional 40,411 shares during the last quarter. Finally, Holocene Advisors LP purchased a new stake in DexCom in the third quarter valued at approximately $163,964,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $72.47 on Friday. The firm has a market cap of $27.96 billion, a P/E ratio of 30.97, a P/E/G ratio of 1.13 and a beta of 1.45. The stock has a 50 day simple moving average of $67.07 and a two-hundred day simple moving average of $67.92. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the business earned $0.32 earnings per share. On average, analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. The trade was a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock worth $3,343,977 in the last ninety days. 0.28% of the stock is currently owned by insiders.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Mizuho set a $85.00 target price on shares of DexCom and gave the company an “outperform” rating in a research report on Tuesday, June 9th. BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Benchmark initiated coverage on shares of DexCom in a report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Finally, Barclays reiterated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.